Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Buechel, Megan, Danielle Enserro, Robert Allen Burger, Mark F. Brady, Katrina Wade, Angeles Alvarez Secord, Andrew B. Nixon, et al. “Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.” In Journal of Clinical Oncology, 36:5507–5507. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5507.

Full Text

Jia, Jingquan, Donna Niedzwiecki, Hope Elizabeth Uronis, Michael Morse, Yousuf Zafar, Shiaowen David Hsu, Emily Bolch, et al. “A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.” In Journal of Clinical Oncology, 36:3555–3555. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3555.

Full Text

Kim, Richard D., Andrew Stewart Poklepovic, Andrew B. Nixon, Dae Won Kim, Heloisa P. Soares, Jongphil Kim, Jun Min Zhou, Fatima Tariq, Natalie Burgess, and Hanna Kelly Sanoff. “Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.” In Journal of Clinical Oncology, 36:4082–4082. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4082.

Full Text

Seligmann, Jenny F., Ace J. Hatch, Susan D. Richman, Faye Elliott, Bart Jacobs, Sarah Brown, Herbert Hurwitz, et al. “Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.” Jama Oncol 4, no. 4 (April 1, 2018): 564–68. https://doi.org/10.1001/jamaoncol.2017.3168.

PMID
29075780
Full Text

Ronald, James, Andrew B. Nixon, Daniele Marin, Rajan T. Gupta, Gemini Janas, Willa Chen, Paul V. Suhocki, et al. “Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma.” Radiology 285, no. 1 (October 2017): 311–18. https://doi.org/10.1148/radiol.2017162555.

PMID
28787261
Full Text

Corradetti, M. N., A. J. Hatch, J. Torok, E. P. Xanthopoulos, C. N. Rushing, J. Calaway, G. Jones, A. B. Nixon, and C. R. Kelsey. “Dynamic Changes in Cell-Free DNA During Chemoradiation for Non–small Cell Lung Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 99:S114–15. Elsevier BV, 2017. https://doi.org/10.1016/j.ijrobp.2017.06.270.

Full Text

Thompson, Eric M., Stephen T. Keir, Talaignair Venkatraman, Christopher Lascola, Kristen W. Yeom, Andrew B. Nixon, Yingmiao Liu, et al. “The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.” Neuro Oncol 19, no. 9 (September 1, 2017): 1217–27. https://doi.org/10.1093/neuonc/nox033.

PMID
28379574
Full Text

Liu, Yingmiao, Zhenhua Yuan, Dadong Zhang, Mark D. Starr, John C. Brady, Manoj A. Jivani, Bonne J. Adams, et al. “Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.” In Journal of Clinical Oncology, 35:11546–11546. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.11546.

Full Text

Sinicrope, Frank A., Fang-Shu Ou, Qian Shi, Andrew B. Nixon, Kabir Mody, Alexandra Levasseur, Amylou C. Dueck, et al. “Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).” In Journal of Clinical Oncology, 35:TPS3630–TPS3630. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.tps3630.

Full Text

George, Daniel J., Susan Halabi, Mark D. Starr, Herbert Hurwitz, John C. Brady, Ian Barak, Michael J. Morris, et al. “Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).” In Journal of Clinical Oncology, 35:4522–4522. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.4522.

Full Text

Pages